- Documentoinforme (1)cargado poralvaro.bosch.ibanez
- Documentojamaneurology_mendell_2021_oi_210023_1624467431.00495cargado poralvaro.bosch.ibanez
- Documentoinformecargado poralvaro.bosch.ibanez
- Documentoinforme (2)cargado poralvaro.bosch.ibanez
- DocumentoAtrofia_muscular_espinalcargado poralvaro.bosch.ibanez
- DocumentoGil Lizarraga, Uxuecargado poralvaro.bosch.ibanez
- DocumentoSpinal Muscular Atrophycargado poralvaro.bosch.ibanez
- DocumentoSpinal muscular atrophy From approved therapies to future therapeutic targets for personalized medicinecargado poralvaro.bosch.ibanez
- DocumentoSafety and efficacy of nusinersen in spinal muscular atrophy The EMBRACE studycargado poralvaro.bosch.ibanez
- DocumentoNew and Developing Therapies in Spinal Muscularcargado poralvaro.bosch.ibanez
- DocumentoExpert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophycargado poralvaro.bosch.ibanez
- DocumentoFive-Year Extension Results of the Phase 1 START Trialcargado poralvaro.bosch.ibanez
- DocumentoAdvances and limitations for the treatment of spinal muscular atrophycargado poralvaro.bosch.ibanez